Menopause & Perimenopause

Menopause is defined as 12 months without a menstrual period, and in the US it arrives at an average age of about 51. Perimenopause, the transition before it, usually starts in the mid-40s and can last several years. Estrogen and progesterone swing unpredictably, cycles become irregular, and symptoms often start well before periods stop. The most common symptoms are hot flashes and night sweats (vasomotor symptoms, which affect most women and in the SWAN cohort lasted a median of about 7 years), disrupted sleep, mood changes and brain fog. Many women also notice vaginal dryness and painful sex (genitourinary syndrome of menopause), lower libido, joint aches, fat moving to the abdomen, and changes in their skin. Less visibly, bone loss speeds up sharply around the final period.

The foundation of treatment is well established. The Menopause Society's 2022 position statement calls hormone therapy the most effective treatment for hot flashes and genitourinary symptoms, and notes that it prevents bone loss and fracture. For healthy women under 60, or within 10 years of their final period, it judges the benefit-risk balance favorable. Low-dose vaginal estrogen treats vaginal and urinary symptoms with minimal absorption into the bloodstream. For women who cannot or prefer not to use hormones, there are evidence-backed non-hormonal options: cognitive behavioral therapy, SSRIs and SNRIs, gabapentin, and two new drugs that block neurokinin receptors in the brain. These are fezolinetant (Veozah, FDA-approved 2023) and elinzanetant (Lynkuet, FDA-approved October 2025).

'Peptides for menopause' content online mixes two very different things. One is FDA-approved peptide drugs with strong evidence for specific menopause-related problems: GLP-1 drugs for weight and PTH analogs for osteoporosis. The other is gray-market and compounded peptides with no menopause trials at all. This page works through the evidence symptom by symptom, so it is clear which peptide (if any) has data for which problem. Two points frame everything: peptides do not replace estrogen or hormone therapy, and no peptide is approved for hot flashes. This page is informational, not medical advice.

How peptides target menopause & perimenopause

Midlife weight and belly fat. As estrogen falls, fat storage shifts from the hips and thighs toward the abdomen, including visceral fat around the organs. Age-related muscle loss lowers daily energy use, and poor sleep makes appetite harder to control. Semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 agonist) act on appetite and satiety centers in the brain and slow stomach emptying. They are FDA-approved for chronic weight management whatever a woman's menopausal status. They do not act on sex hormones; they work on the weight regardless of the cause.

Postmenopausal osteoporosis. Estrogen restrains the cells that break down bone, so losing it speeds up bone loss. The loss is fastest in the years around the final period, roughly 2% a year at the spine. Teriparatide (a fragment of parathyroid hormone, PTH 1-34) and abaloparatide (an analog of PTH-related protein) are given as daily injections. Because each dose is a brief pulse, they stimulate bone-building osteoblasts more than they stimulate breakdown, so they build new bone. Most osteoporosis drugs, by contrast, only slow loss. Both are FDA-approved for postmenopausal women with osteoporosis at high fracture risk.

Vaginal dryness and atrophy. Vaginal tissue has oxytocin receptors. Intravaginal oxytocin gel has been proposed as a way to improve blood flow and the maturation of the vaginal lining without estrogen. That idea appeals most to women who want to avoid estrogen, such as some breast cancer survivors.

Low libido. PT-141 (bremelanotide, Vyleesi) activates melanocortin-4 receptors in the brain, which increases sexual desire. It is FDA-approved only for premenopausal women with acquired hypoactive sexual desire disorder (HSDD). It is not approved after menopause.

Hot flashes. The biology here is genuinely about peptides, which is why kisspeptin comes up so often. Hot flashes start in a group of hypothalamic neurons called KNDy neurons, named for the three peptides they release: kisspeptin, neurokinin B and dynorphin. Once estrogen feedback is gone, these neurons enlarge and become overactive, and neurokinin B signaling to the brain's temperature-control center sets off flushes. In a small Imperial College study, an infusion of neurokinin B caused hot flushes in 8 of 10 women. Fezolinetant and elinzanetant work by blocking neurokinin receptors. They are small-molecule oral drugs, not peptides. Giving kisspeptin does not block this pathway. It stimulates LH release, and LH is already high after menopause because the ovaries no longer respond.

Skin. Estrogen loss reduces skin collagen, often quoted as about 30% in the first five years after menopause. GHK-Cu, a copper peptide used in skincare, stimulates collagen and remodels the skin's supporting tissue in cosmetic studies.

Growth hormone secretagogues. CJC-1295, ipamorelin, sermorelin and tesamorelin often appear in clinic 'menopause protocols' on the reasoning that growth hormone declines with age. No trial has tested any of them for menopausal symptoms. Tesamorelin's only FDA approval is for reducing excess abdominal fat in HIV-associated lipodystrophy.

What the evidence shows

Strongest evidence: bone. Teriparatide and abaloparatide have pivotal fracture trials in postmenopausal women. In the Fracture Prevention Trial (Neer et al., NEJM 2001), teriparatide 20 mcg daily cut new vertebral fractures by 65% and nonvertebral fractures by 53% over a median of 21 months. In the ACTIVE trial (Miller et al., JAMA 2016), abaloparatide cut new vertebral fractures by 86% compared with placebo. Guidelines reserve these drugs for women at high or very high fracture risk (very low T-scores, prior fragility fractures, or fracture despite other treatment). They are usually followed by an antiresorptive drug so the gains are not lost.

Strong evidence: weight. The GLP-1 obesity trials enrolled mostly women, many of them in midlife, and there is now menopause-specific analysis. In a post hoc analysis of SURMOUNT-1 (Tchang et al., Obesity 2025), tirzepatide reduced body weight by about 23% in both perimenopausal and postmenopausal women, compared with about 3% on placebo, with waist circumference falling by roughly 20 cm. It was sponsor-funded and post hoc, but it rests on a randomized comparison. For semaglutide, menopause-specific data are observational. In a retrospective Mayo Clinic cohort (Hurtado et al., Menopause 2024), 106 postmenopausal women took semaglutide. The 16 also using hormone therapy lost about 16% of body weight at 12 months, against 12% for those not using it. The study was small and does not prove cause and effect. A 2026 Spanish Menopause Society position statement reached a similar conclusion: direct menopause-specific evidence for incretin drugs is still limited and largely observational, even though the general obesity evidence is very strong.

Weak and mixed evidence: vaginal oxytocin. The largest randomized trial (Fianu Jonasson et al., 2020; 157 women treated for 12 weeks) found that an oxytocin gel worked no better than the same gel without oxytocin; symptoms improved similarly in both groups. A smaller Egyptian trial (50 women, 2 weeks) reported better vaginal pH and cell maturation with oxytocin gel. A 2023 meta-analysis found mixed results, and one 2018 trial was retracted in 2024. No intravaginal oxytocin product is FDA-approved. Vaginal estrogen, vaginal DHEA (prasterone), ospemifene and moisturizers all have far stronger evidence.

Libido after menopause: no approved peptide. PT-141's RECONNECT trials enrolled premenopausal women and showed modest improvements in desire. Neither of the two FDA-approved HSDD drugs (bremelanotide and flibanserin) is approved for postmenopausal women. For postmenopausal HSDD, transdermal testosterone has the best evidence, though it is off-label in the US. Treating vaginal atrophy also often improves sexual function.

Hot flashes: no peptide evidence. Hormone therapy remains the most effective treatment. Among non-hormonal drugs, elinzanetant reduced moderate-to-severe hot flashes by about three more episodes per day than placebo at week 12 in the OASIS 1 and 2 trials, and fezolinetant showed similar benefit in its SKYLIGHT trials. The Menopause Society lists weight loss as a lower-evidence non-hormonal option for hot flashes, but no randomized trial has measured hot flashes as an outcome of GLP-1 treatment. Kisspeptin has never been tested as a treatment for menopausal symptoms.

No menopause data: growth hormone secretagogues, BPC-157, MOTS-c and the other peptides commonly sold in 'menopause stacks'. For GHK-Cu, the data come from small cosmetic studies of topical products, not from trials in menopausal women.

What to expect

GLP-1 drugs (semaglutide, tirzepatide). The commonly discussed regimens are the labeled ones: weekly injections increased gradually over several months to limit nausea. In the pivotal trials, average weight loss was about 15% with semaglutide and about 21% with the top tirzepatide dose over roughly 16–18 months, with meaningful reductions in waist size. Nausea, constipation and reflux are common early on. Some muscle and bone is lost along with fat, which matters more for women already at risk of osteoporosis or sarcopenia, so resistance training and adequate protein are part of doing this well. Weight usually returns if the drug is stopped. Women in perimenopause can still get pregnant. Tirzepatide's label advises switching from oral contraceptives to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase. Semaglutide's label advises stopping at least 2 months before a planned pregnancy.

PTH analogs (teriparatide, abaloparatide). Labeled dosing is a daily subcutaneous injection: teriparatide 20 mcg or abaloparatide 80 mcg. Courses usually run 18–24 months; abaloparatide's label still advises against more than 2 years of total lifetime use. Spine bone density rises noticeably within the first year. An antiresorptive drug (a bisphosphonate or denosumab) should follow to keep the gain. Common side effects include dizziness on standing, leg cramps, nausea and raised blood calcium.

Vaginal oxytocin. Trial protocols used a daily intravaginal gel (400 IU for 12 weeks in the largest trial). At most, expect modest changes. The largest trial could not separate oxytocin from the plain gel it was mixed in.

PT-141. The labeled dose is 1.75 mg injected under the skin about 45 minutes before sex, for premenopausal women only. Nausea affects roughly 40% of users. It has not been shown to work after menopause.

All doses above are commonly discussed label or trial figures for reference only. Whether any of these drugs suits you, and at what dose, should be decided and supervised by a clinician who knows your history.

What NOT to expect from any peptide: relief from hot flashes or night sweats, restored estrogen, a reversed or delayed menopause, regular cycles again, or a substitute for hormone therapy or vaginal estrogen in women who would benefit from them.

Frequently asked questions

References

• The 2022 hormone therapy position statement of The North American Menopause SocietyGuideline

  The Menopause Society's (formerly NAMS) core statement: hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and prevents bone loss and fracture. For women under 60 or within 10 years of menopause without contraindications, the benefit-risk ratio is favorable.

• The 2023 nonhormone therapy position statement of The North American Menopause SocietyGuideline
• Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT programPost Hoc Analysis of RCTs

  Tchang et al., Obesity 2025 (sponsor-authored). In SURMOUNT-1, tirzepatide reduced body weight by 26% in premenopausal, 23% in perimenopausal and 23% in postmenopausal women, versus 2–3% on placebo, with waist reductions of about 20 cm. These are the clearest randomized data on a GLP-1-class drug by menopausal stage.

• Weight loss response to semaglutide in postmenopausal women with and without hormone therapy useRetrospective Cohort
• Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosisRandomized Controlled Trial
• Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical TrialRandomized Controlled Trial
• Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (Vagivital®) in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy: A Randomized, Double-Blind Controlled StudyRandomized Controlled Trial

  The largest trial of intravaginal oxytocin (157 postmenopausal women, 12 weeks). Oxytocin gel (400 IU daily) and the same gel without oxytocin both reduced the most bothersome atrophy symptoms, with no significant difference between them. The improvement came from the gel, not the oxytocin.

• Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical TrialsRandomized Controlled Trial

Part of these goals

Related conditions

• Vaginal Atrophy
• Low Libido (Women)
• Osteoporosis
• Insomnia
• Brain Fog
• Skin Aging & Wrinkles

Stacks that overlap

• PT-141 + Oxytocin (The Intimacy Stack)

  Combines PT-141's central arousal signaling with oxytocin's bonding and emotional connection effects for a comprehensive approach to sexual wellness and intimacy.

• CagriSema / CagriTriz / CagriReta (Cagrilintide + GLP-1 Agonist)

  A family of weekly injectable obesity stacks that pair the long-acting amylin analog cagrilintide with a GLP-1 receptor agonist — semaglutide (CagriSema), tirzepatide (CagriTriz), or retatrutide (CagriReta). Only CagriSema has completed pivotal clinical trials; the other two are conceptual compounded or investigational combinations.